Ultragenyx Pharmaceutical
RARE
100 hedge funds and large institutions have $1.5B invested in Ultragenyx Pharmaceutical in 2014 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 46 increasing their positions, 19 reducing their positions, and 8 closing their positions.
248% more call options, than puts
Call options by funds: $2.69M | Put options by funds: $775K
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
142% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 19
84% more capital invested
Capital invested by funds: $816M → $1.5B (+$683M)
23% more funds holding
Funds holding: 81 → 100 (+19)
Top Buyers
Top Sellers
RARE Hedge Fund Activity: Q3 2014 in Review
100 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2014, worth a combined $1.5B — up 84% from $816M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new RARE positions and 8 closed out — a net gain of 19 holders — while 46 added to existing stakes and 19 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $88.7M. The largest seller was Adage Capital Partners, cutting an estimated $35.6M.
- 100 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2014, up from 81 in Q2 2014.
- Funds reported $1.5B of Ultragenyx Pharmaceutical stock for Q3 2014, up 84% quarter-over-quarter.
- 27 funds opened new Ultragenyx Pharmaceutical positions in Q3 2014 and 8 closed out, a net change of +19 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2014 was Capital Research Global Investors, an estimated $88.7M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2014 was Adage Capital Partners, an estimated $35.6M sold.
Based on aggregated 13F filings for Q3 2014.